3Mertens I, Van-Gaal LF. Obesity haemostasis and the fibrinolytie system [J]. Obes Rev, 2002, 3(2): 85-101.
4Zethelius B, Lithell H, Hales C N, et al.Insulin sensitivity, pro-insulin and insulin as predictors of coronary heart disease. Apopulation-based 10-year, follow-up study in 70- year old men using the euglycaemic insulin clamps [J]. Diabetologia. 2005. 48(5): 862-867.
5Mogelvang R, Scharling H, Jensen J S. A simple linear model for the effect of changes in metabolic risk factors on coronary heart disease[J]. J Intern Med, 2006,259(6): 561- 568.
6Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome:links,causes,and consequences[J]. Arterioscler Thromb Vasc Biol, 2006, 26(10):2200-2207.
7Mertens I, Verrijken A, Michiels JJ, et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome[J]. Int J Obes, 2006, 30(8): 1308-1314.
8Valle Jimenez M, Estepa RM, Camacho RM, et al. Endothelial dysfunction is related to insulin resistance and inflammatory biomarker levels in obese prepubertal children[J]. Eur J Endocrinol, 2007, 156(4):497-502.
9Natali A, Toschi E, Baldeweg S, et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes[J]. Diabetes, 2006,55(4):1133- 1140.
10Lip GY, Blann AD. Plasma von Willebrand factor and the development of the metabolic syndrome inpatients with hypertension[J]. J Clin Endocrinol Metab,2004, 89(11):5377- 5381.
